KR960703588A - 인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response) - Google Patents

인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response) Download PDF

Info

Publication number
KR960703588A
KR960703588A KR1019960700714A KR19960700714A KR960703588A KR 960703588 A KR960703588 A KR 960703588A KR 1019960700714 A KR1019960700714 A KR 1019960700714A KR 19960700714 A KR19960700714 A KR 19960700714A KR 960703588 A KR960703588 A KR 960703588A
Authority
KR
South Korea
Prior art keywords
sexual response
medicament
methods
modulation
drug
Prior art date
Application number
KR1019960700714A
Other languages
English (en)
Other versions
KR100391025B1 (ko
Inventor
아드리안 더블유. 조르그니오티
다이앤-마리 지오코
Original Assignee
죠셉 에스. 포돌스키
조나겐, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22311403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960703588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 죠셉 에스. 포돌스키, 조나겐, 인코오포레이티드 filed Critical 죠셉 에스. 포돌스키
Publication of KR960703588A publication Critical patent/KR960703588A/ko
Application granted granted Critical
Publication of KR100391025B1 publication Critical patent/KR100391025B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Control Of Fluid Pressure (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 "1차-통과" 효과를 배제하는 투여 경로에 의해 순환계로 혈관확장제를 투여함으로써, 인간의 성적 감응을 조절하는 개선된 방법에 관한 것이다.

Description

인간의 성적 감응을 조절하는 방법(METHODS FOR MODULATING THE HUMAN SEXUAL RESPONSE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 20mg 용량의 펜톨아민 메실레이트를 협측 투여한 후 음경의 동맥혈 속도에 대한 변화율을 도시한 그래프이다.

Claims (5)

  1. 인간의 성적 감응을 조절하기 위한 목적의, 경점막, 경피, 비강내 및 직장 투여용 약제를 제조하는데 혈관확장 활성을 가진 약물을 사용하는 방법.
  2. 제1항에 있어서, 상기 약물이 펜톨아민 메실레이트, 펜톨아민 하이드로클로라이드, 페녹시벤즈아민, 요힘빈, 니트로글리세린, 티목스아민, 이미프라민, 베라파밀, 이속스수프린, 나프티드로푸릴, 톨라졸린 및 파파베린으로 이루어진 군중에서 선택된 것임을 특징으로 하는 사용 방법.
  3. 남성의 발기불능을 치료하기 위한 목적의, 경점막 투여용 약제를 제조하는데 펜톨아민 메실레이트를 함유한 약물을 사용하는 방법.
  4. 제3항에 있어서, 상기 약제가 정제형인 것을 특징으로 하는 사용 방법.
  5. 제4항에 있어서, 상기 각 정제가 약 5mg 내지 약 80mg의 펜톨아민 메실레이트를 함유하는 것을 특징으로 하는 사용 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700714A 1993-08-13 1994-08-10 인간의성적감응을조절하는방법 KR100391025B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10643493A 1993-08-13 1993-08-13
US08106434 1993-08-13
US08/106,434 1993-08-13

Publications (2)

Publication Number Publication Date
KR960703588A true KR960703588A (ko) 1996-08-31
KR100391025B1 KR100391025B1 (ko) 2003-10-04

Family

ID=22311403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700714A KR100391025B1 (ko) 1993-08-13 1994-08-10 인간의성적감응을조절하는방법

Country Status (16)

Country Link
US (1) US5565466A (ko)
EP (1) EP0714300B1 (ko)
JP (1) JP3782101B2 (ko)
KR (1) KR100391025B1 (ko)
CN (1) CN1103589C (ko)
AT (1) ATE174795T1 (ko)
BR (1) BR9407250A (ko)
CA (1) CA2169071C (ko)
DE (1) DE69415535T2 (ko)
DK (1) DK0714300T3 (ko)
ES (1) ES2127409T3 (ko)
GR (1) GR3029500T3 (ko)
NO (1) NO311785B1 (ko)
NZ (1) NZ271567A (ko)
WO (1) WO1995005172A1 (ko)
ZA (1) ZA946123B (ko)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) * 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
FR2748658B1 (fr) * 1996-05-15 2000-08-18 Biotec Centre Sa Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
CA2262789A1 (en) * 1996-08-09 1998-02-19 Jerome H. Abrams Male impotence diagnostic ultrasound system
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
ATE333279T1 (de) * 1997-05-19 2006-08-15 Zonagen Inc Kombinationstherapie zur modulation der humanen sexualreaktion
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
EP0998274B1 (en) 1997-06-23 2006-01-18 Cellegy Pharmaceuticals, Inc Microdose therapy of vascular conditions by no donors
EP1535611A3 (en) * 1997-06-23 2009-09-16 Strakan International Limited Microdose therapy of vascular conditions by no donors
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6251076B1 (en) 1997-08-01 2001-06-26 Urometrics Inc. Male impotence diagnostic ultrasound system
US5947901A (en) 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
AUPP010397A0 (en) * 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
TW380045B (en) 1998-01-13 2000-01-21 Urometrics Inc Devices and methods for monitoring female arousal
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
FR2774594A1 (fr) * 1998-02-12 1999-08-13 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
WO2000012110A2 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
MXPA01010021A (es) * 1999-04-06 2002-07-30 Zonagen Inc Metodos para la modulacion de la respuesta sexual humana..
US6214849B1 (en) 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6405219B2 (en) 1999-06-22 2002-06-11 F5 Networks, Inc. Method and system for automatically updating the version of a set of files stored on content servers
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
DE60131644T2 (de) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
US20040137081A1 (en) * 2003-01-13 2004-07-15 Peter Rohdewald Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
CA2417552C (en) 2000-06-27 2014-05-13 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
MXPA03007081A (es) * 2001-02-08 2004-10-15 Pharmacia Corp Medicamento de accion rapida para el tratamiento de disfuncion sexual.
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US20030158184A1 (en) * 2001-12-21 2003-08-21 Garvey David S. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
BRPI0511079A (pt) * 2004-05-11 2007-12-26 Emotional Brain Bv usos de uma combinação de um inibidor de pde5 e testosterona ou de um seu análogo, e de testosterona ou de um seu análogo, formulação farmacêutica, e, kit de partes
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2349104B1 (en) * 2008-10-10 2015-12-23 Kirk Promotion LTD. Stimulation of penis erection
US8939889B1 (en) 2013-08-22 2015-01-27 Coloplast A/S Pump bulb for an implantable penile prosthetic
US11622730B2 (en) * 2014-11-17 2023-04-11 Rochester Institute Of Technology Pulse wave velocity, arterial compliance, and blood pressure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943246A (en) * 1972-07-10 1976-03-09 Sandoz Ltd. Organic compounds
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
WO1990015583A1 (en) * 1989-06-16 1990-12-27 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Device for treating sexual weakness in men
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence

Also Published As

Publication number Publication date
KR100391025B1 (ko) 2003-10-04
NO960549L (no) 1996-04-12
BR9407250A (pt) 1996-09-24
CN1128950A (zh) 1996-08-14
NO311785B1 (no) 2002-01-28
EP0714300A4 (en) 1996-07-24
EP0714300B1 (en) 1998-12-23
US5565466A (en) 1996-10-15
CN1103589C (zh) 2003-03-26
CA2169071C (en) 2008-10-21
AU7523894A (en) 1995-03-14
GR3029500T3 (en) 1999-05-28
JPH09501677A (ja) 1997-02-18
ATE174795T1 (de) 1999-01-15
EP0714300A1 (en) 1996-06-05
DK0714300T3 (da) 1999-08-23
AU696815B2 (en) 1998-09-17
DE69415535D1 (de) 1999-02-04
NO960549D0 (no) 1996-02-12
DE69415535T2 (de) 1999-06-17
ES2127409T3 (es) 1999-04-16
CA2169071A1 (en) 1995-02-23
NZ271567A (en) 1997-12-19
ZA946123B (en) 1995-03-20
WO1995005172A1 (en) 1995-02-23
JP3782101B2 (ja) 2006-06-07

Similar Documents

Publication Publication Date Title
KR960703588A (ko) 인간의 성적 감응을 조절하는 방법(methods for modulation the human sexual response)
DK1178783T3 (da) Indretning og anvendelse til forögelse af den transdermale permeation af lægemidler
BRPI0410542A (pt) dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
HUP0004347A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
AR001739A1 (es) Uso de un vasodilatador para la producción de una formulación para modular la repuesta sexual humanay dicha formulación
DE69332758D1 (de) Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DE3787377D1 (de) Eindringungserhöhende mittel zur transdermalen verabreichung systemischer mittel.
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
ATE122885T1 (de) Mittel zur behandlung von herzerkrankungen.
FR2387220A1 (fr) Derives du benzimidazole et medicaments qui en contiennent
DK0538302T3 (da) Reduktion eller forhindring af hudirritation forårsaget af lægemidler
ATE292453T1 (de) Antivirale arznei
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
YU42098A (sh) Upotreba olanzapina
PT89123A (pt) Metodo para a utilizacao de d1-5-{(2-benzil-3,4-di-hidro-2h-benzopiran-6-il)metil}tiazolidino-2,4-diona como agente anti-aterosclerose

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
AMND Amendment
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120608

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20130612

Year of fee payment: 11